TY  - JOUR
AU  - Valgimigli, Marco
AU  - Smits, Pieter C
AU  - Frigoli, Enrico
AU  - Bongiovanni, Dario
AU  - Tijssen, Jan
AU  - Hovasse, Thomas
AU  - Mafragi, Al
AU  - Ruifrok, Willem Theodoor
AU  - Karageorgiev, Dimitar
AU  - Aminian, Adel
AU  - Garducci, Stefano
AU  - Merkely, Bela
AU  - Routledge, Helen
AU  - Ando, Kenji
AU  - Diaz Fernandez, Josè Francisco
AU  - Cuisset, Thomas
AU  - Nesa Malik, Fazila Tun
AU  - Halabi, Majdi
AU  - Belle, Loic
AU  - Din, Jehangir
AU  - Beygui, Farzin
AU  - Abhyankar, Atul
AU  - Reczuch, Krzysztof
AU  - Pedrazzini, Giovanni
AU  - Heg, Dik
AU  - Vranckx, Pascal
AU  - MASTER DAPT Investigators
PY  - 2022
DO  - 10.1093/eurheartj/ehac284
UR  - http://hdl.handle.net/10668/19770
T2  - European heart journal
AB  - To assess the effects of 1- or ≥3-month dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents for complex percutaneous coronary intervention (PCI) and/or acute coronary...
LA  - en
KW  - Complex intervention
KW  - Dual antiplatelet therapy
KW  - High bleeding risk
KW  - Percutaneous coronary intervention
KW  - Acute Coronary Syndrome
KW  - Aspirin
KW  - Drug Therapy, Combination
KW  - Hemorrhage
KW  - Humans
KW  - Myocardial Infarction
KW  - Percutaneous Coronary Intervention
KW  - Platelet Aggregation Inhibitors
KW  - Stroke
KW  - Treatment Outcome
TI  - Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis.
TY  - research article
VL  - 43
ER  -